NICE Recommends BioCryst's Hereditary Angioedema Med

The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's BCRX Orladeyo (berotralstat) for hereditary angioedema (HAE).
The recommendation covers eligible patients 12 years and older if they have at least two attacks per month.
With this recommendation, patients in England, Wales, and Northern Ireland will have access to the first oral, once-daily therapy for routine prevention of recurrent HAE attacks.
The decision follows the European Commission marketing authorization of Orladeyo in April 2021 and approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2021.
A decision from the Scottish Medicines Consortium (SMC) for the use of Orladeyo is anticipated in the first half of 2022.
Read Next: BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder.
Price Action: BCRX stock is 0.56% lower at $14.99 during the market session on the last check Thursday.